MacuCLEAR is developing MC 1101 for the treatment and prevention of the progression of age related macular degeneration (AMD).
Mystic Pharmaceuticals said that it has developed a novel unit dose drug delivery platform capable of preservative free, precision delivery of ophthalmic drugs.
Timothy Sullivan, president and CEO of Mystic Pharmaceuticals, said: “We are pleased to work with MacuCLEAR in their clinical program. Their drug has shown promise throughout its preclinical program and has received fast track status from the FDA. Our delivery systems are uniquely designed to safely and effectively deliver drugs to low vision and elderly people. The combination of these two technologies offers great potential for addressing a terrible disease resulting in loss of vision.”